Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection.
Adult
Aged
COVID-19
/ diagnosis
COVID-19 Nucleic Acid Testing
Comorbidity
Female
Hospitalization
Humans
Laboratories
Male
Mexico
/ epidemiology
Middle Aged
Reinfection
/ diagnosis
Retrospective Studies
Risk Factors
SARS-CoV-2
/ isolation & purification
Severity of Illness Index
Symptom Assessment
Treatment Outcome
Young Adult
COVID-19
Cohort studies
Prognosis
Reverse transcription polymerase chain reaction
Severe acute respiratory syndrome coronavirus 2
Journal
Public health
ISSN: 1476-5616
Titre abrégé: Public Health
Pays: Netherlands
ID NLM: 0376507
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
15
10
2020
revised:
19
01
2021
accepted:
30
01
2021
pubmed:
29
3
2021
medline:
14
5
2021
entrez:
28
3
2021
Statut:
ppublish
Résumé
The aim of the study was to evaluate factors predicting severe symptomatic laboratory-confirmed (via Reverse transcription polymerase chain reaction, RT-PCR polymerase chain reaction) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection. This is a nationwide retrospective cohort study that was conducted in Mexico. Data from 258 reinfection cases (at least 28 days between both episodes onset) were analyzed. We used risk ratios (RRs) and 95% confidence intervals (CIs) to evaluate predictors of severe (dyspnea requiring hospital admission) secondary SARS-CoV-2 infection. The risk of severe disease was 14.7%, and the observed overall fatality rate was 4.3%. Patients with more serious primary disease were more likely to develop severe symptoms (39.5% vs. 5.5%, P < 0.001) during reinfection. In multiple analysis, factors associated with an increased risk of severe symptomatic SARS-CoV-2 reinfection were increasing age (RR To the best of our knowledge, this is the first study evaluating disease outcomes in a large set of laboratory-positive cases of symptomatic SARS-CoV-2 reinfection, and factors associated with illness severity were characterized. Our results may contribute to the current knowledge of SARS-CoV-2 pathogenicity and to identify populations at increased risk of a poorer outcome after reinfection.
Identifiants
pubmed: 33774512
pii: S0033-3506(21)00043-3
doi: 10.1016/j.puhe.2021.01.021
pmc: PMC7879028
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113-115Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.
Références
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
J Infect. 2021 Feb;82(2):282-327
pubmed: 32800801
Saf Health Work. 2020 Sep;11(3):262-265
pubmed: 32995051
BMC Infect Dis. 2020 Sep 16;20(1):674
pubmed: 32938419
J Infect. 2020 Oct;81(4):647-679
pubmed: 32417316